European Regulators Recommend Biogen Idec, Inc. (Massachusetts)'s (JOBS) Tysabri Label Update

Bookmark and Share

Reuters -- European regulators have identified 31 cases of a potentially deadly brain infection in patients taking Biogen Idec Inc's (BIIB.O) multiple sclerosis drug Tysabri and recommended new measures for dealing with the risks of the drug.
MORE ON THIS TOPIC